#151037

Anti-Cdk1 [17 (A17)]

Cat. #151037

Anti-Cdk1 [17 (A17)]

Cat. #: 151037

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Cyclin dependent kinase 1 (Cdk1, cdc2)

Class: Monoclonal

Application: ELISA ; IHC ; IP ; WB

Reactivity: Chicken ; Human ; Mouse ; Rat ; Xenopus laevis

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Julian Gannon

Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Cdk1 [17 (A17)]
  • Alternate name: Cyclin-Dependent Kinase 1; Cell Division Cycle 2, G1 To S And G2 To M; Cell Division Control Protein 2 Homolog; Cell Division Protein Kinase 1; P34 Protein Kinase; P34CDC2; CDC28A; CDC2; Cell Cycle Controller CDC2; CDKN1
  • Research fields: Cancer;Cell biology;Neurobiology
  • Clone: 17 (A17)
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 34 kDa
  • Strain: Balb/c
  • Reactivity: Chicken ; Human ; Mouse ; Rat ; Xenopus laevis
  • Host: Mouse
  • Application: ELISA ; IHC ; IP ; WB
  • Description: Cdk1 (Cdc2) is a serine/threonine kinase which forms complexes with cyclins A and B which then phosphorylate a variety of target substrates to enable cell cycle progression. Therefore, Cdk1 is a marker for proliferating tumour cells.
  • Immunogen: A carboxy-terminal fragment starting at methionine 85 of p34 cdc2 (Xenopus laevis).
  • Isotype: IgG2a
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: Tonsil

Target Details

  • Target: Cyclin dependent kinase 1 (Cdk1, cdc2)
  • Molecular weight: 34 kDa
  • Tissue cell line specificity: Tonsil
  • Target background: Cdk1 (Cdc2) is a serine/threonine kinase which forms complexes with cyclins A and B which then phosphorylate a variety of target substrates to enable cell cycle progression. Therefore, Cdk1 is a marker for proliferating tumour cells.

Applications

  • Application: ELISA ; IHC ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Zhou et al. 2015. Platelets. :1-11. PMID: 26325015.
  • Platelets promote cartilage repair and chondrocyte proliferation via ADP in a rodent model of osteoarthritis.
  • Coulonval et al. 2011. Mol Biol Cell. 22(21):3971-85. PMID: 21900495.
  • Coupling of T161 and T14 phosphorylations protects cyclin B-CDK1 from premature activation.
  • Gannon et al. 1998. Genes Cells. 3(1):17-27. PMID: 9581979.
  • A measure of the mitotic index: studies of the abundance and half-life of p34cdc2 in cultured cells and normal and neoplastic tissues.
  • Goodger et al. 1996. J Pathol. 178(4):422-8. PMID: 8691321.
  • The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity.
  • Doussis-Anagnostopoulou et al. 1994. Histopathology. 24(4):335-40. PMID: 8045523.
  • Distribution of the cdc2 gene product in normal tissues: an immunocytochemical study using four new monoclonal antibodies.
  • Kobayashi et al. 1992. Mol Biol Cell. 3(11):1279-94. PMID: 1333843.
  • Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits.